Evaxion Biotech A/S EVAX 深 沪
等待开盘 12-20 09:30:00 美东时间
4.7542
-0.996
-17.32%
华盛通- 最 高6.92
- 今 开5.65
- 成交量 37.09万股
- 最 低 4.6516
- 昨 收 5.75
- 总市值 1.11亿
- 52周最高 12.1499
- 市盈率 静 --
- 换手率 1.59%
- 52周最低 0.8092
- 委 比 93.32%
- 总股本 2325.79万
- 历史最高 25.04
- 量 比 5.72
- 振 幅 39.45%
- 历史最低 0.4701
- 每 手 1
- 风险率 1.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out
Merck declines its option on Evaxion's EVX-B2 gonorrhea vaccine, leaving global rights with Evaxion and no change to its cash runway through 2027.
今天 01:43
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Evaxion receives grant funding to design new polio vaccine
Evaxion Biotech received a grant from the Gates Foundation to develop a new polio vaccine using its AI-Immunology platform, aiming to eradicate the disease and address current vaccine limitations.
06-03 13:15
Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025
Evaxion A/S will provide a business update and report Q1 2025 financial results on May 27 at 14:30 CET/08:30 EST. A conference call and webcast, open to the public, will discuss the update and take questions. To join, register via the provided link to receive dial-in details and a PIN. The webcast can be accessed through the event link.
05-23 12:00
Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01
Evaxion A/S has initiated a one-year extension of its phase 2 trial for EVX-01, a personalized cancer vaccine for advanced melanoma. The extension aims to explore the vaccine's potential as monotherapy after initial combination treatment, assess long-term immune and clinical benefits, and generate additional clinical data with minimal costs. The trial remains on track for two-year data readout in late 2025.
05-22 12:00
HC Wainwright & Co. Reiterates Buy on Evaxion Biotech, Maintains $14 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion Biotech (NASDAQ:EVAX) with a Buy and maintains $14 price target.
2024-09-20 18:35
Evaxion Biotech Unveils Pre-Clinical Results for mRNA-Based Gonorrhea Vaccine
Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new pre-clinical data demonstrating the ability of its novel
2024-09-09 19:03
European Equities Traded in the US as American Depositary Receipts Edge Lower Friday; Set to End Week Up 0.5%
11:10 AM EDT, 08/30/2024 (MT Newswires) -- European equities traded in the US as American depositary receipts edged lower late Friday morning, nudging down 0.03% to 1,476.31 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by medical device maker EDAP TMS (EDAP) and ...
2024-08-30 23:10
